Translate this page into:
175Yb-TTHMP for bone pain palliation
Address for correspondence: Prof. Sim Sai Tin, Medical Center, Shantou, China. E-mail: simsaitin@gmail.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
We would like to discuss on the publication on “175Yb-TTHMP for bone pain palliation.”[1] Safarzadeh proposed “175Yb-TTHMP can be a good candidate for bone pain palliation and substitute of other radiopharmaceuticals.”[1] The production of 175Yb is the first consideration. Since preparation of 175Yb requires specific standard atomic chemistry center, it might be limited prepared and distributed for actual clinical usage.[2] Second, since 175Yb is rather limited study, its actual effect and adverse effect are still unknown. Dosage that can be problematic has never been clarified, and this is an issue for further studying.[3] Finally, to control of bone pain, not only finding the new palliative agent but also the good holistic care, including psychological support, is needed.[4]
REFERENCES
- 175Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals. Indian J Nucl Med. 2014;29:135-9.
- [Google Scholar]
- Feasibility study for production of 175Yb: A promising therapeutic radionuclide. Appl Radiat Isot. 2002;57:295-301.
- [Google Scholar]
- Scab incidence on pig skin resulting from hot particle exposures under varying conditions. Health Phys. 2001;81:47-56.
- [Google Scholar]
- Palliative radiotherapy of bone metastases: An evaluation of outcome measures. J Eval Clin Pract. 2001;7:47-64.
- [Google Scholar]